• 1
    Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995; 211(Suppl.): 358.
  • 2
    Dimenas E, Glise H, Hallerback B, et al. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand J Gastroenterol 1993; 28: 6817.
  • 3
    Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. Scand J Gastroenterol 1993; 28(Suppl. 199): 1821.
  • 4
    Revicki DA, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. Am J Med 1998; 104: 2528.
  • 5
    Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98(Suppl.): S814.
  • 6
    Armstrong D, Veldhuyzen van Zanten SJO, Barkun AN, et al. Symptom response at 1-week predicts responders at 4-weeks with esomeprazole (40 mg bid and od) in patients with uninvestigated dyspepsia. Am J Gastroenterol 2003; 98(Suppl.): 48S-9S.
  • 7
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): II6977.
  • 8
    Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1998; 57: 109112.
  • 9
    Blazeby JM, Williams MH, Alderson D, Farndon JR. Observer variation in assessment of quality of life in patients with oesophageal cancer. Br J Surg 1995; 82: 12001203.
  • 10
    Fisch MJ, Titzer ML, Kristeller JL, et al. Assessment of quality of life in outpatients with advanced cancer: the accuracy of clinician estimations and relevance of spiritual well-being – A Hoosier Oncology Group Study. J Clin Oncol 2003; 21: 27549.
  • 11
    Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self ratings? Qual Life Res 1997; 6: 22536.
  • 12
    Litwin MS, Lubeck DP, Henning JM, Carroll PR. Differences in urologist and patient assessment of health related quality of life in men with prostate cancer: results of the CaPSURE database. J Urol 1998; 159: 198892.
  • 13
    Sneeuw KCA, Aaronson NK, Sprangers MAG, Detmar SB, Wever LDV, Schornagel JH. Evaluating the quality of life of cancer patients: assessments by patients, significant others, physicians and nurses. Br J Cancer 1999; 81: 8794.
  • 14
    Grassi L, Indelli M, Maltoni M, Falcini F, Fabbri L, Indelli R. Quality of life of homebound patients with advanced cancer: assessments by patients, family members and oncologists. J Psychosoc Onc 1996; 14: 3145.
  • 15
    Lampic C, Sjődén PO. Patient and staff perceptions of cancer patients’ psychological concerns and needs. Acta Oncol 2000; 39: 922.
  • 16
    Hewlett SA. Patients and clinicians have different perspectives on outcomes in arthritis. J Rheumatol 2003; 30: 8779.
  • 17
    Carr AJ, Donovan JL. Why doctors and patients disagree. Br J Rheumatol 1998; 37: 16.
  • 18
    Suarez-Almazor ME, Conner-Spady B, Kendall CJ, Russell AS, Skeith K. Lack of congruence in the ratings of patients’ health status by patients and their physicians. Med Decis Making 2001; 21: 11321.
  • 19
    Lieberman JR, Dorey F, Shekelle P, et al. Differences between patients’ and physicians’ evaluations of outcome after total hip arthroplasty. J Bone Joint Surg 1996; 78A: 8358.
  • 20
    Schünemann HJ, Armstrong D, Fallone C, et al. A randomized multi-center trial to evaluate simple utility elicitation techniques in patients with gastro esophageal reflux disease. Med Care 2004; 42: (in press).
  • 21
    Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 10239.
  • 22
    Schünemann HJ, Griffith L, Stubbing D, Goldstein R, Guyatt GH. A clinical trial to evaluate the responsiveness and validity of two direct health state preference instruments administered with and without hypothetical marker states in chronic respiratory disease. Med Decis Making 2003; 23: 1409.
  • 23
    Schünemann HJ, Guyatt GH, Stahl E, et al. A comparison of presenting hypothetical health states in narrative and point-by-point format: results from two randomized trials. Med Decis Making 2004; 24: 5360.
  • 24
    Bennet KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off, and standard gamble techniques. Chapter27 in Spilker B. Quality of life and pharmacoeconomics in clinical trials, Second Edition. Philadelphia: Lippincott-Raven, 1996: 259.
  • 25
    Torrance GW, Furlong W, Feeny DH, Boyle M. Multiattribute preferences functions: health utilities index. Pharmacoecon 1995; 6: 50320.
  • 26
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). conceptual framework and item selection. Med Care 1992; 30: 47383.
  • 27
    Talley NJ, Fullerton S, Junghard O, Wiklund I. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001; 96: 19982004.
    Direct Link:
  • 28
    Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease specific questionnaire (QOLRAD). Eur J Surg 1998; 583(Suppl.): 419.
  • 29
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining the minimally important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 817.
  • 30
    Loonen HJ, Derkx BHHF, Griffiths AM. Pediatricians overestimate importance of physical symptoms upon children's health concerns. Med Care 2002; 40: 9961001.
  • 31
    Rothwell PM, McDowell Z, Wong CK, Dorman PJ. Doctors and patients don't agree: cross sectional study of patients’ and doctors’ perceptions and assessments of disability in multiple sclerosis. BMJ 1997; 314: 15803.
  • 32
    Yen JC, Neville C, Fortin PR. Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials. Lupus 1999; 8: 66070.
  • 33
    Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003; 18: 87582.
  • 34
    Dent J. Initial therapy of reflux disease with esomeprazole. Aliment Pharmacol Ther 2003; 17(Suppl. 1): 1820.
  • 35
    Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gasro-oesophageal reflux disease: a controlled trial of ‘on demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.